StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

81 Study Matches

MT2015-25: Tandem Myeloablative Consolidation Therapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

To evaluate 3 year progression free survival (PFS) rate of high-risk neuroblastoma patients after treatment with a tandem consolidation of Thiotepa/ Cyclophosphamide and PBSC rescue followed by Carboplatin/Etoposide/ Melphalan (CEM) and PBSC rescue, as compared to historical controls of a single CEM consolidation course with PBSC rescue.

Status: Recruiting
Contact(s):

Holly Franceen - hfrancee@umn.edu

Principal Investigator: Alex Hoover
Age: Not specified
Phase: PHASE2
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 16776
Show full eligibility criteria
Hide eligibility criteria
Age: Not specified
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• less than 30 years old when diagnosis of neuroblastoma is made
• no uncontrolled infection
• recovered from acute toxicities of last cycle of induction chemotherapy
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Conditions: Cancer
Keywords: Neuroblastoma
I'm interested
Share via email
See this study on ClinicalTrials.gov

Prospective quantitative kinematic assessment of patients with normal pressure hydrocephalus

This is a prospective study aimed at quantifying walking and balance in normal pressure hydrocephalus (NPH) patients in the clinical setting. To accomplish this, we will use a portable motion capture system that is widely used to study biomechanics in humans. Once quantified, we want to test the effects of ventriculoperitoneal shunt (VPS) on walking and balance among NPH patients. Thus, our objectives are: Aim 1: We will demonstrate the use of quantitative kinematic data on NPH patients pre-lumbar drain, post-lumbar drain and post-VPS in order to assess the predictive value of CSF removal on gait and balance. Aim 2: We will demonstrate the use of objective, neuropsychological data on NPH patients pre-lumbar drain, post-lumbar drain and post-VPS in order to assess the predictive value of CSF removal on cognition 3. We will demonstrate the use of objective, physical therapy data on NPH patients pre-lumbar drain, post-lumbar drain and post-VPS in order to assess the predictive value of CSF removal on therapeutic intervention in terms of walking and balance measures.

Status: Recruiting
Contact(s):

Thomas Lisko - tlisko@umn.edu

Principal Investigator: Robert McGovern, MD
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 31198
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:
People who are suspected of having Normal Pressure Hydrocephalus (NPH) and scheduled to have inpatient admission for a trial lumbar drain
Exclusion Criteria:

• People who have dementia of sufficient severity to impair their ability to make health-care decisions
• People who have other types of Parkinson's Disease
• People who are unable to stand without help
Conditions: Brain & Nervous System
Keywords: Balance, Dementia, Hydrocephalus, Incontinence, Normal pressure hydrocephalus, aging
I'm interested
Share via email

Natural History Study for DNA Repair Disorders

A single-center, single-arm, non-interventional natural history study to evaluate the longitudinal clinical course, functional outcome measures, and candidate biomarkers for individuals with DNA repair disorders, including Cockayne syndrome (CS), xeroderma pigmentosum (XP), and trichothiodystrophy (TTD).

Status: Recruiting
Contact(s):

Seth Stafki - stafk006@umn.edu

Principal Investigator: Peter Kang
Age: Not specified
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 38563
Show full eligibility criteria
Hide eligibility criteria
Age: Not specified
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 6 months old
• diagnosis of Cockayne syndrome (CS), xeroderma pigmentosum (XP), or trichothiodystrophy (TTD), based on genetic testing and/or key clinical characteristics
• have one or more of the neurodevelopmental or neurological complications such as gross motor delay, language delay, altered muscle tone (study staff will review)
• family member of an individual with the above condition
Exclusion Criteria:

• prior history of systemic gene or cell-based therapy
• participation in a clinical trial for treatment
Conditions: Rare Diseases
Keywords: Cockayne Syndrome, DNA Repair Disorder, Trichothiodystrophy, Xeroderma Pigmentosum, Clinics and Surgery Center (CSC)
I'm interested
Share via email
See this study on ClinicalTrials.gov

Neural Bases of Disgust Conditioning in Anorexia Nervosa

We are studying the brain patterns of people who have anorexia nervosa and those who don't have anorexia nervosa. We will look at MRIs, behavioral measures, and questionnaires to see if we can identify the brain activity associated with disgust. There will be a follow-up at 6 and 12 months.

Status: Recruiting
Contact(s):

Claire McDonald - mcdo1202@umn.edu

Principal Investigator: Lisa M Anderson
Age: 18 years and over
Healthy Volunteers:
This study is also accepting healthy volunteers
System ID: 29820
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is also accepting healthy volunteers
Inclusion Criteria:

• Anorexia Nervosa Participants: females between 18- 50 years old who meet criteria for diagnosis of Anorexia Nervosa
• Healthy Participants: healthy females age between 18-50, no previous diagnosis of Anorexia Nervosa or other psychiatric disease.
Exclusion Criteria:

• Meets criteria for substance abuse disorder or actively suicidal
• Neurological condition or other developmental disorder
• MRI contraindication
• Inability to read English
Conditions: Mental Health & Addiction
Keywords: Anorexia, Eating Disorder, Mental Health
I'm interested
Share via email

Prefrontal Cortical Stimulation in Severe Treatment Resistant Depression

This study looks at the use of an implanted brain stimulator for people who have treatment resistant depression. The change in brain function by EEG and symptoms of depression will be examined. This study is open to people 22-70 years old with Medicare or Medicare Advantage insurance.

Status: Recruiting
Contact(s):

Interventional Psychiatry Lab Study - ipl@umn.edu

Principal Investigator: Ziad Nahas
Age: 18 years and over
Phase: NA
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 25193
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• ages 22-55
• diagnosis of chronic (greater than or equal to 2 years) depression
• poor response to three or more antidepressant medications (staff will review)
• had or refused ECT therapy
• under the regular care of a psychiatrist
• enrolled in a Medicare program
• have at least two people over 22 years of age and live within 30 minutes of participants residence who could respond to study staff if needed
• able to have a MRI scan
Exclusion Criteria:

• actively suicidal or have a history of an attempt within the last year
• have a history of another major mental health diagnosis
• have a positive drug test
• have an implanted brain device
• pregnant
• history of seizures
Conditions: Mental Health & Addiction
Keywords: Chronic Depression, Clinics and Surgery Center (CSC), Depression
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Randomized Double Blind Phase II Trial of Restorative Microbiota Therapy (RMT) or Placebo in Combination with Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Treatment Naïve Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer

This is a randomized, active-controlled, parallel-group, double-blind Phase II trial, of oral restorative microbiota therapy (RMT) or placebo combined with intravenous (IV) durvalumab (MEDI4736) plus tremelimumab and chemotherapy in patients with treatment naïve advanced or metastatic adenocarcinoma non-small cell lung cancer (NSCLC). The primary objectives include: -To evaluate the efficacy of restorative microbiota therapy (RMT) in combination with durvalumab and tremelimumab plus chemotherapy compared with placebo in combination with durvalumab and tremelimumab plus chemotherapy using PFS per RECIST 1.1 as assessed by the investigator -To evaluate the safety and feasibility of restorative microbiota therapy (RMT) in combination with durvalumab and tremelimumab plus chemotherapy in patients with untreated advanced or metastatic adenocarcinoma non-small cell lung cancer (NSCLC)

Status: Recruiting
Contact(s):

Greg Lee - glee413@umn.edu

Principal Investigator: Manish Patel
Age: 18 years and over
Phase: PHASE2
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 27034
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• confirmed adenocarcinoma of the lung that is stage IIIB/C or stage IV that can't be surgically removed
• prior chemotherapy or immunotherapy as adjuvant therapy for lung cancer is permitted as long as it has been more than 6 months from last dose
• people who have treated brain metastasis are eligible as long as they have stable symptoms, are more than 2 weeks from completion of therapy, and do not require more than 10mg of daily prednisone or equivalent
• restricted in strenuous physical activity but can walk and carry out work of a light or sedentary nature, e.g., light house work, office work
• weigh at least 30 kg (66 lbs.)
• contact study staff for additional requirements
Exclusion Criteria:

• women who are pregnant or breast feeding
• unable to swallow medications
• additional medical and mental health diagnosis (study staff will review)
Conditions: Cancer, Respiratory System
Keywords: Adenocarcinoma of Lung, Clinics and Surgery Center (CSC), Lung Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

MT2016-11 :Autologous Stem Cell Transplant In Patients with Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL)

The primary objective is to estimate overall survival (OS) at 3 years post-transplant for patients who received the radiation free preparative regimen.

Status: Recruiting
Contact(s):

Veronika Bachanova - bach0173@umn.edu

Age: Not specified
Phase: PHASE2
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 19183
Show full eligibility criteria
Hide eligibility criteria
Age: Not specified
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• up to 75 years of age
• diagnosis of Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Mature B cell Lymphoma, or Mature T cell Lymphoma
• at least 4 weeks from previous chemotherapy; 6 weeks from nitrosoureas
• women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment
• see link to clinicaltrials.gov for complete criteria
Exclusion Criteria:

• women who are pregnant or breastfeeding
• chemotherapy resistant disease
• unrelated active infection
Conditions: Cancer
Keywords: Clinics and Surgery Center (CSC), Hodgkin Lymphoma, Non-Hodgkin Lymphoma
I'm interested
Share via email
See this study on ClinicalTrials.gov

I-SPY 2 TRIAL -Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2 (I-SPY)

To determine whether adding experimental agents to standard neoadjuvant paclitaxel (with or without trastuzumab), doxorubicin, and cyclophosphamide increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry, and to determine for each experimental agent used, the predictive probability of success in a subsequent phase 3 trial for each possible biomarker signature.

Status: Recruiting
Contact(s):

Douglas Yee - yeexx006@umn.edu

Principal Investigator: Douglas Yee, MD
Age: 18 years and over
Phase: PHASE2
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 38844
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• invasive breast cancer confirmed by biopsy
• tumor is at least 2.5 cm in size
• no prior chemotherapy for this cancer
• no restrictions in activity or partially restricted with work, but able to independently care for self
• willing to have another breast biopsy
• not pregnant or breast feeding
• consult study staff for additional requirements
Exclusion Criteria:

• other medical or mental health diagnosis that would limit compliance with study requirements
Conditions: Cancer
Keywords: Breast Cancer, Breast Tumors, Clinics and Surgery Center (CSC), I-SPY, ISPY, ISPY2
I'm interested
Share via email
See this study on ClinicalTrials.gov

10,000 Families Study

The purpose of this study is to study the evolution of early life risk factors that may lead to cancer and other conditions. This is a prospective cohort study of families who reside in Minnesota.

Status: Recruiting
Contact(s):

tenkfs STUDY - tenkfs@umn.edu

Principal Investigator: Jen Poynter
Age: Not specified
Healthy Volunteers:
This study is also accepting healthy volunteers
System ID: 20212
Show full eligibility criteria
Hide eligibility criteria
Age: Not specified
Healthy Volunteers:
This study is also accepting healthy volunteers
Inclusion Criteria:

• 1st Participant: 18+ living in MN
• Other family members: All ages and must live in MN, ND, SD, IA, or WI
• Participants ages 0-17 must have a parent consent to their participation and assist with study activities
Exclusion Criteria:

• Unwilling or unable to provide DNA and blood sample
• Does not have at least 1 living family member in MN IA, ND, SD, or WI
Conditions: Cancer, Microbiota, Prevention & Wellness
Keywords: 10KFS, D2D, environment, exposures, family, genetics, glyphosate, lifestyle, Minnesota, PFAS, radon
I'm interested
Share via email

Post-contracture release radiation for Dupuytren's disease

The purpose of this study is to critically assess the current treatment that patients are undergoing by reviewing routine data collected and adding one additional outcome questionnaire solely for research purposes

Status: Recruiting
Contact(s):

Lydia Golden - golde406@umn.edu

Principal Investigator: Leslie Chang
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 21650
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 18 years old
• diagnoses of Dupuytren's disease
• English-speaking
Exclusion Criteria:

• people who have Dupuytren's disease and are not currently seeking treatment
Keywords: Dupuytren Contracture, Dupuytren's Disease
I'm interested
Share via email
See this study on ClinicalTrials.gov

Vibrotactile stimulation of the larynx to treat unexplained chronic cough

This is a study of adults with unexplained chronic cough between 18-80 years old. This study is trying to determine whether a noninvasive vibrotactile stimulation device can help reduce cough symptoms.

Status: Recruiting
Contact(s):

Ali Stockness - nicho656@umn.edu

Principal Investigator: Stephanie Misono
Age: 18 years and over
Phase: NA
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 31596
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• adults aged 18-88
• more than 8 weeks of non-productive cough
• chest x-ray or chest CT negative (collected as part of routine clinical care); no time limit on imaging (if available)
• clinical impression that untreated or inadequately treated gastroesophageal, pulmonary, and/or sinus or nasal issue is not the reason for the cough
• able to read and speak English
Exclusion Criteria:

• current smoker or quit less than 3 months ago
• infectious cause for cough (e.g., TB, pertussis, COVID)
• history of known or suspected aspiration pneumonia
• Diagnosis or clinical suspicion of chronic obstructive pulmonary disease (COPD)
• Diagnosis or clinical suspicion of interstitial lung disease (ILD)
• Unmanaged reflux
• Unmanaged allergies/postnasal drip
• recent intubation/neck surgery (within 8 weeks)
• neuromuscular impairment that may affect cough/laryngeal sensation and/or function (e.g., multiple system atrophy, Parkinson, CVA)
• untreated carotid artery disease
• electronic implants (e.g., pacemaker)
• specific medications (study staff will discuss)
• anticipate use of new medications to treat the cough during the period of the study
• currently having speech therapy for cough
• BMI > 40 (for transmission of VTS through soft tissue)
• allergy to adhesives
• Current or recent drug/alcohol dependency or abuse (stopped or completed treatment less than 6 months)
• pregnant
• without regular access to wifi and internet
Conditions: Breathing, Lung & Sleep Health, Ear, Nose & Throat
Keywords: chronic cough, Clinics and Surgery Center (CSC), cough, larynx, vibrotactile stimulation
I'm interested
Share via email
See this study on ClinicalTrials.gov

The effects of cigarette smoking and alcohol on DNA damage in the oral cavity

The purpose of this study to examine the effects of cigarette smoking and drinking alcohol on the formation of DNA damage in the mouth. The overall goal is to identify DNA damage that may be important to the development of head and neck cancers.

Status: Recruiting
Contact(s):

Smoking Alcohol Study - smoking-alcohol@umn.edu

Principal Investigator: Stephen Hecht, PhD
Age: 18 years and over
Healthy Volunteers:
This study is also accepting healthy volunteers
System ID: 36605
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is also accepting healthy volunteers
Inclusion Criteria:

• Healthy individuals
• over 30 years old
• have 7 or more alcoholic drinks per week
Exclusion Criteria:

• Use tobacco/nicotine products
• Unstable health
Conditions: Cancer, Prevention & Wellness
Keywords: drinking, ADH, Alcohol, beer, liquor
I'm interested
Share via email

Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (REBOOT)

This trial is a two-part study (Part A and Part B) of adults with primary membranous nephropathy, ages 18-75 inclusive. Part A is an open-label, PK phase to compare belimumab exposure between participants who have “low” proteinuria (≥ 4 to < 8 g/day) and “high” proteinuria (≥ 8 g/day) at Visit -1. Part B is a prospective, randomized, phase II, double-blind, placebo-controlled, multicenter clinical trial in adults with primary MN. Part B will commence after the analysis of the PK data in Part A.

Status: Recruiting
Contact(s):

Patrick Nachman - pnachman@umn.edu

Principal Investigator: Patrick Nachman
Age: 18 years and over
Phase: PHASE2
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 26698
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18 to 75 years old
• diagnosis of Membranous Nephropathy (MN) or Nephrotic Syndrome (study staff will review specific requirements)
• hypertension while on maximum medications i.e. systolic BP greater than 140mmHg or diastolic greater than 90mmHg
Exclusion Criteria:

• Rituximab use within the previous 12 months
• poorly controlled diabetes mellitus defined as hemoglobin A1c (HbA1c) 9.0% or greater
• women of child-bearing age who are pregnant, nursing, or unwilling to be sexually inactive or use FDA-approved contraception for the duration of the study
• additional medical and mental health exclusions apply, study staff will review
Conditions: Kidney, Prostate & Urinary
Keywords: Clinics and Surgery Center (CSC), Membranous Nephropathy, Nephrotic Syndrome
I'm interested
Share via email
See this study on ClinicalTrials.gov

Randomized Clinical Evaluation of the AccuCinch Ventricular Restoration System in Patients who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)

The objective of this study is to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with symptomatic heart failure with reduced ejection fraction (HFrEF).

Status: Recruiting
Contact(s):

Melanie Farinella - crawl027@umn.edu

Principal Investigator: Greg Helmer
Age: 18 years and over
Phase: NA
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 33805
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 18 years old
• Ejection Fraction: between 20% and 40% measured by transthoracic echocardiography (TTE)
• diagnosis and treatment for heart failure should be established at least 90 days before entering the study & should be on stable, optimal medical therapy for at least 30 days
Exclusion Criteria:

• myocardial infarction or any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 90 days prior to consent
• any planned cardiac surgery or interventions within the next 180 days
• women who are pregnant, planning to become pregnant, or are breast feeding
• additional cardiac and medical diagnosis will exclude participation (study staff will review)
Conditions: Heart & Vascular
Keywords: Clinics and Surgery Center (CSC), Dilated Cardiomyopathy, Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
I'm interested
Share via email
See this study on ClinicalTrials.gov

Mechanisms and effects of pallidal deep brain stimulation on levodopa resistant motor signs in Parkinson's disease; Udall Project 2, Aim 2

1.1 Purpose: This protocol will carry out Aim 2 (Experiments 1 and 3) of Udall Project 2, leveraging the novel (on-label, FDA-approved) local field potential measuring capability of the Medtronic Percept™ PC DBS system to study the effects of globus pallidus internus and globus pallidus externus (GPi, GPe) DBS on: the wash-out and wash-in dynamics of motor behavior and local field potentials (LFPs) and correlations between fluctuations in gait and LFPs during activities of daily living (recorded over 4 weeks).

Status: Recruiting
Contact(s):

Kristin Garland - garl0038@umn.edu

Principal Investigator: Colum MacKinnon
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 37325
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• receiving DBS therapy in for treatment of Parkinson's Disease (PD)
• implanted with Medtronic Percept DBS system
• at least 3 months since initial activation of the DBS
Exclusion Criteria:

• musculoskeletal disorders that significantly affect the ability to perform the motor tasks
• dementia or cognitive impairment
• other significant neurological disorders
• post-operative complications or adverse effects of the DBS stimulation
Conditions: Brain & Nervous System
Keywords: Clinics and Surgery Center (CSC), DBS, Deep Brain Stimulator, Parkinson Disease, aging
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (EPPIK) (EPPIK)

Currently, there are no approved treatment options for pediatric subjects with proteinuric kidney conditions. The study will look at the safety, efficacy, and pharmacokinetic (PK)trial in children ≥1 to <18 years treated for up to 108 weeks with the drug sparsentan.

Status: Recruiting
Contact(s):

Anael Kuperwajs Cohen - kuper029@umn.edu

Principal Investigator: Michelle Rheault
Age: Up to 18 years old
Phase: PHASE2
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 33702
Show full eligibility criteria
Hide eligibility criteria
Age: Up to 18 years old
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Child 1 to 18 years old
• Diagnosed by biopsy with specific types of glomerular disease & protein in the urine
• Blood pressure is within normal range for age
• Maintained on a stable dose of immunosuppressive medications
Exclusion Criteria:

• Weight less than 7.3 kg 16 pounds) at screening.
• Disease due to to viral infections, drug toxicities, or cancer.
• Kidney function is below the minimum required
Conditions: Children's Health, Kidney, Prostate & Urinary, Rare Diseases
Keywords: Alport Syndrome, Glomerulosclerosis, IgA Vasculitis, Immunoglobulin A Nephropathy
I'm interested
Share via email
See this study on ClinicalTrials.gov

Cardiac Sarcoidosis Consortium

This is a registry study. The Cardiac Sarcoidosis Consortium (CSC) is an international, multicenter partnership among physicians and allied professionals at major medical centers with the unifying purpose to learn more about cardiac sarcoidosis through collaborative research.

Status: Recruiting
Contact(s):

Maddy Chopp - chopp015@umn.edu

Principal Investigator: Henri Roukoz
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 16347
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• People who have been diagnosed with Cardiac sarcoidosis (CS)
• History of ventricular tachycardia or fibrillation
• Ventricular arrhythmias treated medically or with an implanted device
Conditions: Heart & Vascular
Keywords: ablation, cardiac ablation, Cardiac sarcoidosis, Ventricular Tachycardia
I'm interested
Share via email

MT2013-06C : Treatment of graft Failure after HSCT

The objectives of this study are to assess the following: - Incidence of sustained donor engraftment at day 42 post transplant - Incidence of transplant related mortality (TRM) at day 100 - Overall survival at day 100 and 1 year - Acute GVHD after this second transplant at day 100 and 6 months - Chronic GVHD after this second transplant at day 12 and 24 months

Status: Recruiting
Contact(s):

Timothy Krepski - tkrepsk1@fairview.org

Principal Investigator: Troy Lund
Age: Not specified
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 15449
Show full eligibility criteria
Hide eligibility criteria
Age: Not specified
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• patients with primary or secondary HSCT graft failure
• see link to clinicaltrials.gov for complete Inclusion and Exclusion criteria
Exclusion Criteria:

• uncontrolled infection at the time of transplant
• patients with Fanconi Anemia or other DNA breakage syndromes
Keywords: Clinics and Surgery Center (CSC), Failure, Hematopoietic Stem Cell Transplantation, HSCT
I'm interested
Share via email
See this study on ClinicalTrials.gov

ALX-HPP-501: An Observational,Longitudinal Prospective, Long-term Registry of Patients with Hypophosphatasia

This is a long-term registry is designed to collect data on hypophosphatasia (HPP) to better understand the condition and learn more about the disease, how patients feel about living with HPP and effect of HPP on the patients wellbeing and health. The study will look at participant’s medical records and health questionnaires about the health status of patients. This study collects observational data from clinical care and does not involve any treatment for HPP or administration of medication for HPP.

Status: Recruiting
Contact(s):

Kyriakie Sarafoglou - saraf010@umn.edu

Principal Investigator: Kyriakie Sarafoglou
Age: Not specified
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 22992
Show full eligibility criteria
Hide eligibility criteria
Age: Not specified
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• confirmed diagnosis of HPP.
• documented alkaline phosphatase (ALP) activity below the lower limit of normal for age and sex, or a documented ALPL gene mutation.
• able to read and speak English
Exclusion Criteria:

• currently participating in an Alexion-sponsored clinical trial
Conditions: Rare Diseases
Keywords: HPP, Hypophosphatasia
I'm interested
Share via email
See this study on ClinicalTrials.gov

Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry (IPF/ILD-PRO)

Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life of IPF participants, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) established at the enrolling centers. In addition, blood samples will be collected and banked for future research projects.

Status: Recruiting
Contact(s):

Mandi DeGrote - carl1032@umn.edu

Principal Investigator: Hyun Kim
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 20690
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 30 years old
• new diagnosis of Idiopathic Pulmonary Fibrosis (IPF) -diagnosis of a non-IPF Interstitial Lung Disease (ILD) of any duration, including, but not limited to Idiopathic Non-Specific Interstitial, Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis
Exclusion Criteria:

• Cancer, treated or untreated, other than skin or early stage prostate cancer, within the past 5 years
• currently waiting for lung transplantation
• currently enrolled in a clinical trial
Conditions: Respiratory System
Keywords: Clinics and Surgery Center (CSC), Idiopathic Pulmonary Fibrosis (IPF) Interstitial Lung Disease
I'm interested
Share via email
See this study on ClinicalTrials.gov

Autonomic and Vascular Mechanisms of Cardiovascular Risk in Women with Post-traumatic Stress-Disorder (PTSD)

Having PTSD is associated with a higher risk of developing Cardiovascular Disease (CVD), which presents a major health risk for women, who are twice as likely as men to develop PTSD. The purpose of this study is to learn more about the mechanisms behind the relationship between PTSD and increased cardiovascular risk. Ultimately, our goal is to use the knowledge gained from this research study to help develop intervention and treatment strategies to protect the cardiovascular health of women with PTSD.

Status: Recruiting
Contact(s):

Nest Lab Study - nestlab@umn.edu

Principal Investigator: Ida-Arlaine Fonkoue
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 36562
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• female
• 18 years and older
• pre-menopausal
• must have experienced a past trauma, with or without PTSD Diagnosis
Exclusion Criteria:

• pregnant or breastfeeding
• severe traumatic brain injury
• hypertension
• diabetes
• heart disease
• vascular disease
• illicit drug use within the past 6-months prior to participation
• inability or unwillingness to abstain from nicotine use for at least 12 hours prior to Study Visits 2 & 3
Conditions: Mental Health & Addiction, Women's Health
Keywords: Cardiovascular, Cardiovascular Disease (CVD), female, Post-Traumatic Stress Disorder, PTSD, women
I'm interested
Share via email

MT2019-01: Adrenoleukodystrophy National Registry Study (ALD) and Biobank

In this protocol, we will enroll pediatric, adolescent and adult patients diagnosed with adrenoleukodystrophy (ALD). These patients will include probands diagnosed by newborn screening and their relatives subsequently diagnosed, as well other patients who are diagnosed with ALD due to other presenting signs and symptoms and subsequently were confirmed to have ALD. We will ask consenting subjects to provide a medical history (with verification via medical records), to participate in a semi-annual health survey and provide consent to collect biospecimens. The overarching goal of this work is to engage with families affected by ALD and to assemble a resource of clinical, medical, and biological data that will allow of to better understand the natural history of ALD, and how this is affected by newborn screening. The initial focus will be on patients within Minnesota, but participation will be open to any family interested in the study, as this will be web-based. This registry and biobank, together with other research conducted in tandem, will possibly provide information describing the natural history of ALD and outcomes with interventions. It is anticipated that the data collected will further our understanding of the natural history of the disease, basic biology of adrenoleukodystrophy, diagnosis and outcomes. Ultimately, this research may lead to new avenues for early diagnosis and development of safer and more effective therapies for ALD.

Status: Recruiting
Contact(s):

Rachael Eye - eye00002@umn.edu

Principal Investigator: Ashish Gupta
Age: Not specified
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 24912
Show full eligibility criteria
Hide eligibility criteria
Age: Not specified
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• age 0 to 100
• patient or family member diagnosed with ALD (confirmed by positive VLCFA testing and/or genetic mutation
• patient or family member with known or presumed mutation with ALD based on pedigree or confirmed mutation in ABCD1 gene
• living in the United States and territories
Exclusion Criteria:

• have undergone BMT or other cellular therapy
• not fluent in English who are unable to consent in-person
• people who are unable to read or write
Conditions: Rare Diseases
Keywords: Adrenoleukodystrophy, ALD, Cerebral Adrenoleukodystrophy
I'm interested
Share via email
See this study on ClinicalTrials.gov

Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1): Potential Use of Antioxidant/Anti-inflammatory Medications

The purpose of this study is to measure levels of blood and brain chemicals related to oxidative stress and inflammation in healthy volunteers and individuals with Type 1 Gaucher disease (GD1) to see if these levels are altered by GD1. We will also examine if there is a change in these blood and brain chemicals after participants begin taking oral N-acetylcysteine (NAC), which is available both as a prescription medication and a natural product that has antioxidant and anti-inflammatory effects.

Status: Recruiting
Contact(s):

Reena Kartha - rvkartha@umn.edu

Principal Investigator: James Cloyd
Age: 18 years and over
Phase: PHASE2
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 19782
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18 years or older
• diagnosis of Type 1 Gaucher's Disease (GD1) who are medically stable
• on a stable medication therapy for 2 years, or if dosage or drug has been changed it has been at least 6 months and condition is stable
Exclusion Criteria:

• women who are pregnant or breast feeding
• asthma that is currently being treated
• unable to have a MRI scan
Conditions: Rare Diseases
Keywords: Gaucher disease
I'm interested
Share via email
See this study on ClinicalTrials.gov

MT2012-11C: Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

This is a treatment guideline for a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen, consisting of busulfan, fludarabine, and low dose total body irradiation (TBI), is designed to promote engraftment in patients who failed to achieve an acceptable level of donor-derived engraftment following a previous allogeneic HSCT. While it will primarily be applied for the treatment of non-malignant diseases (NMD), on occasion it may be used to treat patients with malignant disorders as well.

Status: Recruiting
Contact(s):

Teresa Bekkala - tkivist1@fairview.org

Principal Investigator: Troy Lund
Age: Not specified
Phase: NA
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 14660
Show full eligibility criteria
Hide eligibility criteria
Age: Not specified
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• up to 55 years old
• diagnosis of any disease for which a second or greater hematopoietic stem cell transplant (HSCT) is needed
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• women who are pregnant or breastfeeding
• active, uncontrolled infection
• HIV positive
Conditions: Blood Disorders
Keywords: Hematologic Disorders, Hemoglobinopathies, HSCT, Immunodeficiencies, Stem Cell Transplant, Clinics and Surgery Center (CSC)
I'm interested
Share via email
See this study on ClinicalTrials.gov

RCT01437: Proactive infliximab optimization using a pharmacokinetic dashboard versus standard of care in patients with inflammatory bowel disease: The OPTIMIZE Trial

The purpose of this study is to find out if using a computer program (called iDose) to guide infliximab dosing is more effective and safer than using standard infliximab dosing over 52 weeks. All patients in this study will be receiving infliximab as part of their medical care, this study is only looking at two different methods of determining the dose and timing of administration.

Status: Recruiting
Contact(s):

Beiqing Wu - wu000948@umn.edu

Principal Investigator: Byron Vaughn
Age: Not specified
Phase: PHASE4
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 35143
Show full eligibility criteria
Hide eligibility criteria
Age: Not specified
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 16 to 80 years of age
• diagnosis of moderate to severe Crohn's disease (CD) or Ulcerative colitis
• physician intends to prescribe infliximab for treatment
• have not previously taken infliximab
Exclusion Criteria:

• pregnant or breastfeeding
• complications of inflammatory bowel disease (IBD) such as abscess, need for ostomy (study staff review)
• current infection in last 6 months
• other significant medical conditions (heart, lungs, liver, endocrine etc.)
Conditions: Digestive & Liver Health
Keywords: Clinics and Surgery Center (CSC), Crohn's disease
I'm interested
Share via email
See this study on ClinicalTrials.gov

Genetics of Developmental Disorders - Data and Specimen Repository

This project is a data and specimen repository for developmental disorders. Participants provide biological samples and permission to store their health-related data. The purpose is collect and manage these materials for use in biomedical research related to developmental disorders.

Status: Recruiting
Contact(s):

Williams Dobyns - wbdobyns@umn.edu

Principal Investigator: Charles Billington Jr.
Age: Not specified
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 31117
Show full eligibility criteria
Hide eligibility criteria
Age: Not specified
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• All ages
• Individuals with a developmental disorder (mostly but not exclusively developmental brain disorders)
• Parents and other selected relatives of individuals with developmental disorders
Conditions: Brain & Nervous System, Children's Health, Rare Diseases
Keywords: developmental brain disorders, developmental disorders, Genetic disorders
I'm interested
Share via email

Optimization of deep brain stimulation parameters in patients with medically refractory epilepsy

This study will develop a platform for stimulation setting optimization based on power spectral density (PSD) measures. Randomized, controlled trials have demonstrated that stimulation of the anterior nucleus of the thalamus (ANT) suppresses seizures. The central hypothesis tested here will be that PSD measured in the ANT will correlate with seizure frequency and stimulation settings that suppress broadband activity will result in lower seizure rates.

Status: Recruiting
Contact(s):

Robert McGovern - rmcgover@umn.edu

Principal Investigator: Robert McGovern, MD
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 32882
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:
People who have medically refractory epilepsy with a deep brain stimulator in place
Exclusion Criteria:
People who have dementia of sufficient severity to impair their ability to make healthcare related decisions for themselves
Conditions: Brain & Nervous System
Keywords: DBS, Deep Brain Stimulation, Epilepsy
I'm interested
Share via email

Time Restricted Eating as a Viable Alternative to Caloric Restriction for Treating Hyperglycemia in a Population with Type 2 (T2DM) diabetes (SFS3)

Feasibility study to test our overall hypothesis that time restricted eating (TRE) presents a viable alternative to caloric restriction for improving glycemic measures and reducing weight in overweight/obese patients with metformin-only treated Type 2 diabetes (T2DM).

Status: Recruiting
Contact(s):

SFS3 Study - seefoodstudy@umn.edu

Principal Investigator: Lisa Chow
Age: 18 years and over
Phase: NA
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 37403
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18 to 65 years old
• overweight/obese and have type 2 diabetes treated with diet or metformin
• BMI between 25-45 kg/m2
• HbA1c between 6.5-8.5%
• self reported weight must be stable (+/- 5 pounds) for at least 3 months prior to the study
• own a smartphone
Exclusion Criteria:

• women who are pregnant or are planning to become pregnant
• eating disorders
Conditions: Diabetes & Endocrine
Keywords: caloric restriction, intermittent fasting, time restricted eating, Type 2 diabetes
I'm interested
Share via email
See this study on ClinicalTrials.gov

Dissecting the role of acetaldehyde in oral carcinogenesis

The goal of this study is to better understand how drinking alcohol may lead to oral cancers. Acetaldehyde, a chemical formed when the body breaks down alcohol, is believed to play an important role. This study will measure acetaldehyde and DNA damage levels in the mouth of participants after a low dose of alcohol. The levels will be compared between three groups, all having different degrees of risk for developing oral cancer, and with non-drinkers to identify DNA damage that might be important to cancer formation. We also want to understand how alcohol can affect the bacteria in our mouths and how that might impact oral DNA damage.

Status: Recruiting
Contact(s):

Alcohol Study - alcohol-study@umn.edu

Principal Investigator: Silvia Balbo
Age: 18 years and over
Phase: NA
Healthy Volunteers:
This study is also accepting healthy volunteers
System ID: 33324
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is also accepting healthy volunteers
Inclusion Criteria:

• Alcohol drinkers of Eastern Asian descent who experiences flushing (reddening or warming of face and chest) when drinking {ages 21 - 45}
• Alcohol drinkers who have Fanconi Anemia {ages 21+}
• Never drinkers {ages 18 - 45}
Exclusion Criteria:

• Tobacco or nicotine users
Conditions: Prevention & Wellness
Keywords: Alcohol, drinking, Fanconi Anemia, flushing
I'm interested
Share via email
See this study on ClinicalTrials.gov

Visual Perception in Visual Snow Syndrome

The proposed research will measure and compare differences in visual performance and associated neural processing in participants who do or do not experience Visual Snow Syndrome, using a series of well-established psychophysical and imaging paradigms.

Status: Recruiting
Contact(s):

Schallmo Lab Study - schallmolab@umn.edu

Principal Investigator: Michael-Paul Schallmo
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
System ID: 36444
Show full eligibility criteria
Hide eligibility criteria
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Between 18 - 60 years old
• Good general physical health
• No history of other neurological disorders or problems
• Fluent in English
Conditions: Vision & Eyes
Keywords: Visual snow, visual snow syndrome
I'm interested
Share via email
See this study on ClinicalTrials.gov